Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

NUTX vs UHS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NUTX
Nutex Health, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$801M
5Y Perf.-90.5%
UHS
Universal Health Services, Inc.

Medical - Care Facilities

HealthcareNYSE • US
Market Cap$10.68B
5Y Perf.+39.2%

NUTX vs UHS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NUTX logoNUTX
UHS logoUHS
IndustryMedical - Healthcare Information ServicesMedical - Care Facilities
Market Cap$801M$10.68B
Revenue (TTM)$880M$17.76B
Net Income (TTM)$96M$1.52B
Gross Margin47.5%67.6%
Operating Margin31.4%11.5%
Forward P/E8.7x7.3x
Total Debt$351M$5.51B
Cash & Equiv.$186M$138M

NUTX vs UHSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NUTX
UHS
StockApr 22May 26Return
Nutex Health, Inc. (NUTX)1009.5-90.5%
Universal Health Se… (UHS)100139.2+39.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: NUTX vs UHS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NUTX leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Universal Health Services, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
NUTX
Nutex Health, Inc.
The Income Pick

NUTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 2.01
  • Rev growth 82.4%, EPS growth 7.9%, 3Y rev CAGR 58.6%
  • 82.4% revenue growth vs UHS's 9.7%
Best for: income & stability and growth exposure
UHS
Universal Health Services, Inc.
The Long-Run Compounder

UHS is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • 30.8% 10Y total return vs NUTX's -97.8%
  • Lower volatility, beta 0.60, Low D/E 74.3%, current ratio 1.05x
  • Beta 0.60, yield 0.5%, current ratio 1.05x
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthNUTX logoNUTX82.4% revenue growth vs UHS's 9.7%
ValueUHS logoUHSLower P/E (7.3x vs 8.7x)
Quality / MarginsNUTX logoNUTX11.0% margin vs UHS's 8.6%
Stability / SafetyUHS logoUHSBeta 0.60 vs NUTX's 2.01, lower leverage
DividendsUHS logoUHS0.5% yield; 1-year raise streak; the other pay no meaningful dividend
Momentum (1Y)NUTX logoNUTX+14.6% vs UHS's -8.2%
Efficiency (ROA)NUTX logoNUTX10.5% ROA vs UHS's 9.8%, ROIC 38.0% vs 12.3%

NUTX vs UHS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NUTXNutex Health, Inc.
FY 2024
Hospital Division
100.0%$449M
UHSUniversal Health Services, Inc.
FY 2025
Acute Care Hospital Services
57.2%$9.9B
Behavioral Health Services
42.8%$7.4B

NUTX vs UHS — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLNUTXLAGGINGUHS

Income & Cash Flow (Last 12 Months)

NUTX leads this category, winning 4 of 6 comparable metrics.

UHS is the larger business by revenue, generating $17.8B annually — 20.2x NUTX's $880M. Profitability is closely matched — net margins range from 11.0% (NUTX) to 8.6% (UHS). On growth, UHS holds the edge at +9.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNUTX logoNUTXNutex Health, Inc.UHS logoUHSUniversal Health …
RevenueTrailing 12 months$880M$17.8B
EBITDAEarnings before interest/tax$297M$2.7B
Net IncomeAfter-tax profit$96M$1.5B
Free Cash FlowCash after capex$270M$894M
Gross MarginGross profit ÷ Revenue+47.5%+67.6%
Operating MarginEBIT ÷ Revenue+31.4%+11.5%
Net MarginNet income ÷ Revenue+11.0%+8.6%
FCF MarginFCF ÷ Revenue+30.7%+5.0%
Rev. Growth (YoY)Latest quarter vs prior year+2.2%+9.6%
EPS Growth (YoY)Latest quarter vs prior year+154.7%+17.7%
NUTX leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

UHS leads this category, winning 4 of 6 comparable metrics.

At 7.4x trailing earnings, UHS trades at a 43% valuation discount to NUTX's 12.8x P/E. On an enterprise value basis, NUTX's 3.3x EV/EBITDA is more attractive than UHS's 6.1x.

MetricNUTX logoNUTXNutex Health, Inc.UHS logoUHSUniversal Health …
Market CapShares × price$801M$10.7B
Enterprise ValueMkt cap + debt − cash$967M$16.0B
Trailing P/EPrice ÷ TTM EPS12.84x7.38x
Forward P/EPrice ÷ next-FY EPS est.8.73x7.30x
PEG RatioP/E ÷ EPS growth rate0.46x
EV / EBITDAEnterprise value multiple3.27x6.14x
Price / SalesMarket cap ÷ Revenue0.92x0.61x
Price / BookPrice ÷ Book value/share2.15x1.48x
Price / FCFMarket cap ÷ FCF3.26x12.57x
UHS leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

NUTX leads this category, winning 7 of 9 comparable metrics.

NUTX delivers a 22.2% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $21 for UHS. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to NUTX's 0.83x. On the Piotroski fundamental quality scale (0–9), NUTX scores 7/9 vs UHS's 6/9, reflecting strong financial health.

MetricNUTX logoNUTXNutex Health, Inc.UHS logoUHSUniversal Health …
ROE (TTM)Return on equity+22.2%+20.7%
ROA (TTM)Return on assets+10.5%+9.8%
ROICReturn on invested capital+38.0%+12.3%
ROCEReturn on capital employed+43.2%+16.0%
Piotroski ScoreFundamental quality 0–976
Debt / EquityFinancial leverage0.83x0.74x
Net DebtTotal debt minus cash$166M$5.4B
Cash & Equiv.Liquid assets$186M$138M
Total DebtShort + long-term debt$351M$5.5B
Interest CoverageEBIT ÷ Interest expense9.13x10.92x
NUTX leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NUTX leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in UHS five years ago would be worth $11,248 today (with dividends reinvested), compared to $224 for NUTX. Over the past 12 months, NUTX leads with a +14.6% total return vs UHS's -8.2%. The 3-year compound annual growth rate (CAGR) favors NUTX at 20.5% vs UHS's 6.5% — a key indicator of consistent wealth creation.

MetricNUTX logoNUTXNutex Health, Inc.UHS logoUHSUniversal Health …
YTD ReturnYear-to-date-9.2%-22.3%
1-Year ReturnPast 12 months+14.6%-8.2%
3-Year ReturnCumulative with dividends+74.8%+20.8%
5-Year ReturnCumulative with dividends-97.8%+12.5%
10-Year ReturnCumulative with dividends-97.8%+30.8%
CAGR (3Y)Annualised 3-year return+20.5%+6.5%
NUTX leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — NUTX and UHS each lead in 1 of 2 comparable metrics.

UHS is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than NUTX's 2.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricNUTX logoNUTXNutex Health, Inc.UHS logoUHSUniversal Health …
Beta (5Y)Sensitivity to S&P 5002.01x0.60x
52-Week HighHighest price in past year$193.07$246.33
52-Week LowLowest price in past year$77.21$152.33
% of 52W HighCurrent price vs 52-week peak+69.7%+69.2%
RSI (14)Momentum oscillator 0–10059.739.7
Avg Volume (50D)Average daily shares traded197K793K
Evenly matched — NUTX and UHS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates NUTX as "Buy" and UHS as "Hold". Consensus price targets imply 52.3% upside for NUTX (target: $205) vs 35.7% for UHS (target: $232). UHS is the only dividend payer here at 0.47% yield — a key consideration for income-focused portfolios.

MetricNUTX logoNUTXNutex Health, Inc.UHS logoUHSUniversal Health …
Analyst RatingConsensus buy/hold/sellBuyHold
Price TargetConsensus 12-month target$205.00$231.50
# AnalystsCovering analysts243
Dividend YieldAnnual dividend ÷ price+0.5%
Dividend StreakConsecutive years of raises11
Dividend / ShareAnnual DPS$0.80
Buyback YieldShare repurchases ÷ mkt cap+0.6%+9.1%
Insufficient data to determine a leader in this category.
Key Takeaway

NUTX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). UHS leads in 1 (Valuation Metrics). 1 tied.

Best OverallNutex Health, Inc. (NUTX)Leads 3 of 6 categories
Loading custom metrics...

NUTX vs UHS: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is NUTX or UHS a better buy right now?

For growth investors, Nutex Health, Inc.

(NUTX) is the stronger pick with 82. 4% revenue growth year-over-year, versus 9. 7% for Universal Health Services, Inc. (UHS). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Nutex Health, Inc. (NUTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NUTX or UHS?

On trailing P/E, Universal Health Services, Inc.

(UHS) is the cheapest at 7. 4x versus Nutex Health, Inc. at 12. 8x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x.

03

Which is the better long-term investment — NUTX or UHS?

Over the past 5 years, Universal Health Services, Inc.

(UHS) delivered a total return of +12. 5%, compared to -97. 8% for Nutex Health, Inc. (NUTX). Over 10 years, the gap is even starker: UHS returned +30. 8% versus NUTX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NUTX or UHS?

By beta (market sensitivity over 5 years), Universal Health Services, Inc.

(UHS) is the lower-risk stock at 0. 60β versus Nutex Health, Inc. 's 2. 01β — meaning NUTX is approximately 234% more volatile than UHS relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 83% for Nutex Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NUTX or UHS?

By revenue growth (latest reported year), Nutex Health, Inc.

(NUTX) is pulling ahead at 82. 4% versus 9. 7% for Universal Health Services, Inc. (UHS). On earnings-per-share growth, the picture is similar: Universal Health Services, Inc. grew EPS 37. 3% year-over-year, compared to 7. 9% for Nutex Health, Inc.. Over a 3-year CAGR, NUTX leads at 58. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NUTX or UHS?

Universal Health Services, Inc.

(UHS) is the more profitable company, earning 8. 6% net margin versus 8. 1% for Nutex Health, Inc. — meaning it keeps 8. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUTX leads at 31. 5% versus 11. 5% for UHS. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NUTX or UHS more undervalued right now?

On forward earnings alone, Universal Health Services, Inc.

(UHS) trades at 7. 3x forward P/E versus 8. 7x for Nutex Health, Inc. — 1. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUTX: 52. 3% to $205. 00.

08

Which pays a better dividend — NUTX or UHS?

In this comparison, UHS (0.

5% yield) pays a dividend. NUTX does not pay a meaningful dividend and should not be held primarily for income.

09

Is NUTX or UHS better for a retirement portfolio?

For long-horizon retirement investors, Universal Health Services, Inc.

(UHS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60)). Nutex Health, Inc. (NUTX) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UHS: +30. 8%, NUTX: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NUTX and UHS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NUTX is a small-cap high-growth stock; UHS is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

NUTX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 6%
Run This Screen
Stocks Like

UHS

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform NUTX and UHS on the metrics below

Revenue Growth>
%
(NUTX: 2.2% · UHS: 9.6%)
Net Margin>
%
(NUTX: 11.0% · UHS: 8.6%)
P/E Ratio<
x
(NUTX: 12.8x · UHS: 7.4x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.